ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,431.60
-0.04%
US Tech 100
19,168.00
0.52%
다우존스 지수
38,589.16
-0.15%
Bitcoin
66,181.78
0.27%
Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Regeneron Pharmaceuticals Inc (REGN)

  7. Regeneron Pharmaceuticals Inc (REGN) 뉴스

REGN

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:REGN
일자시간출처헤드라인심볼기업
2024/06/1505:26Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/06/1405:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/06/1306:04Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/06/1305:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/06/1305:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/06/1120:00GlobeNewswire Inc.Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)NASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/06/1105:03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/06/0805:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/06/0705:12Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/06/0605:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/06/0605:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/06/0603:24Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/06/0405:36Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/05/3114:05GlobeNewswire Inc.Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPDNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/05/3114:00GlobeNewswire Inc.Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 InflammationNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/05/3005:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/05/2920:15PR Newswire (US)Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial TumorsNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/05/2905:29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/05/2406:03GlobeNewswire Inc.Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCONASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/05/2305:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/05/2205:10Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/05/2103:15GlobeNewswire Inc.Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of MedicineNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/05/1806:57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/05/1805:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/05/1805:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/05/1802:45GlobeNewswire Inc.More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024NASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/05/1607:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/05/1505:21Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/05/1314:00GlobeNewswire Inc.Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)NASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/05/0819:00GlobeNewswire Inc.Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 WeeksNASDAQ:REGNRegeneron Pharmaceuticals Inc
 검색 관련기사 보기:NASDAQ:REGN

최근 히스토리

NASDAQ
MNRK
LSE
ZQ43
Citi Fun 24
NASDAQ
ASYS
Amtech Systems
LSE
FF45
Citi Fun 24
NASDAQ
WCAA
NYSE
AIZP
Assurant
UNSW3
SPELLUSDT
Spell Token
USOTC
MUNLF
Multi Units Luxembourg ETF (GM)
COIN
BUNDETH
Bundles
LSE
94IN
Tokyo El.6%bd
BIT
P1V6N6
NLBNPIT1V6N6 20991231 3....
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유